Heart Failure Management Strategies: New Insights for Managed Care
Jointly provided by
Impact Education, LLC    
This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.

You Are Invited to a LIVE Free CME/CNE/CPE Webcast:
Heart Failure Management Strategies: New Insights for Managed Care

Live Webcast Dates

DAY DATE TIME
Tuesday January 23, 2018 12:00 PM - 1:30 PM ET
Tuesday February 6, 2018 1:00 PM - 2:30 PM ET
Thursday February 8, 2018 12:00 PM - 1:30 PM ET
Tuesday February 27, 2018 1:00 PM - 2:30 PM ET


Register Now

Once registered you will receive login information and reminders via email.

CUTTING EDGE TOPICS
  • Recently published guideline updates for emerging therapies
  • Positioning and utilization management criteria
  • Pharmacoeconomic analyses of treatments options
  • The importance of addressing noncardiac comorbidities and overseeing care transitions
EXPERT FACULTY
Akshay S. Desai, MD, MPH
Director, Heart Failure Disease Management Program
Advanced Heart Disease Section, Cardiovascular Division
Brigham and Women's Hospital
Associate Professor of Medicine
Harvard Medical School
Jeffrey D. Dunn, PharmD, MBA
Vice President
Clinical Strategy and Programs and Industry Relations
MagellanRx Management
Edmund Pezalla, MD, MPH
CEO
Enlightenment Bioconsult, LLC
WHO SHOULD ATTEND?
  • Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
  • Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with heart failure including: physicians, pharmacists, and registered nurses
PROGRAM OVERVIEW

Cardiovascular disease (CVD) remains the leading cause of death in the United States, claiming >614,000 American lives in 2014. Heart failure (HF) is a significant contributor to this mortality, being mentioned in nearly half of all CVD-related deaths and being cited as the primary underlying cause in 68,626 of those deaths. These latter statistics provide a glimpse into the far-reaching effects of HF in terms of morbidity, mortality, and resultant health care and societal costs. Leaders from managed care organizations (MCOs) and other payers have identified the management of heart failure (HF) as a priority area for optimizing clinically - and economically - appropriate care for their members. In light of new drug developments, MCOs and other payer organizations need to appropriately and effectively design benefits that optimize both cost-efficiency and patient outcomes. This activity will improve participants' knowledge and competency to recommend pathways for optimal treatment outcomes, conduct comparative effectiveness research, and design medical and pharmacy benefits.

EDUCATIONAL OBJECTIVES

After completing the activity, participants should be better able to:
  • Describe the recently published guideline updates for emerging therapies in HF, including results from pivotal trials and evidence supporting averted HF-related hospitalizations and/or deaths
  • Apply appropriate positioning and utilization management criteria to facilitate judicious and effective utilization of emerging therapies for HF
  • Characterize the disease burden of HF in the managed care setting as determined by hospitalizations and other components of morbidity and mortality
  • Integrate pharmacoeconomic analyses of treatments options for HF into plan decision making
  • Discuss current economic and logistic barriers to appropriate HF therapy in the managed care setting
  • Illustrate opportunities to facilitate member access to care for HF in the current framework of health plan operations and infrastructure
  • Characterize the importance of addressing noncardiac comorbidities and overseeing care transitions as they pertain to maintaining therapeutic persistence and improving outcomes
  • Employ collaborative strategies for HF management enlisting the input and support of a multidisciplinary team of health care providers
AGENDA
Introduction
Edmund Pezella, MD, MPH
Clinical Scenarios in HF and the Appropriate Use of Emerging Pharmacologic Treatments
Akshay S. Desai, MD, MPH
Considerations in Therapeutic Positioning and Benefit Design for Emerging HF Therapies
Jeffrey D. Dunn, PharmD, MBA
Care Coordination and Disease Management Strategies for Optimal HF Outcomes
Edmund Pezella, MD, MPH
Faculty Idea Exchange

Audience Question and Answer Session

Closing Commentary
ACCREDITATION INFORMATION
Physician Continuing Medical Education
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - 0809-9999-18-008-L01-P

Type of Activity: Application

For Pharmacists: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to the CPE Monitor as required. After receipt of a completed activity evaluation form, you will be provided with instructions to have your credit immediately uploaded to the CPE Monitor.

Continuing Nursing Education
Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
There is no fee for this educational activity.

Policy on Privacy and Confidentiality
Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.

Register Now